PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
30 April 2018 - 3:10PM
REGULATED INFORMATION
GHENT, Belgium, 30 April 2018
- Ablynx [Euronext Brussels and Nasdaq: ABLX]
today announced, in accordance with Article 14 of the Belgian Law
of 2 May 2007 regarding the publication of major shareholdings in
issuers whose securities are admitted to trading on a regulated
market (the "Transparency Law"), that it received two notifications
of shareholdings from UBS Group AG on 26 April 2018.
In a first notification, UBS Group
AG (taking into account the holdings of its subsidiary
undertakings) has notified Ablynx that it has downward crossed the
3% threshold of voting rights held directly by controlled
undertakings and upward crossed the 5% threshold of voting rights
held through financial instruments since 20 April 2018.
In a second notification, UBS Group AG has notified Ablynx that it
has upward crossed the 3% threshold of voting rights held directly
by controlled undertakings and downward crossed the 5% threshold of
voting rights held through financial instruments since 23 April
2018.
UBS Group AG now holds 5,862,135
voting securities of Ablynx, representing 7.79% of the 75,253,667
outstanding voting rights of Ablynx (versus 7.35% notified
previously on 18 April 2018).
The latest notification contains
the following information:
-
Reason for the
notification:
-
Notification by: a parent
undertaking or a controlling person
-
Persons subject to the
notification requirement: USB Group AG
-
Transaction date: 23 April
2018
-
Threshold that is crossed:
3% of securities directly held and 5% of securities held through
financial instruments
-
Denominator: 75,253,667
(status on 23 April 2018)
-
Details of the
notification:
Name of select subsidiaries of UBS |
% of voting rights |
% of voting rights held through financial
instruments* |
Total of both |
UBS
AG |
0.73% |
0.11%1 /
3.03%2 /
0.05%2 /
0.10%3 |
4.02% |
UBS Asset
Management Trust Company |
0.00% |
|
0.00% |
UBS Fund
Management (Luxembourg) S.A. |
0.03% |
|
0.03% |
UBS Fund
Management (Switzerland) AG |
0.03% |
|
0.03% |
UBS Hedge
Fund Solutions LLC |
0.44% |
|
0.44% |
UBS
Limited |
0.13% |
|
0.13% |
UBS
O'Connor LLC |
1.35% |
|
1.35% |
UBS
Switzerland AG |
0.61% |
0.08%1 /
0.99%2 /
0.10%2 |
1.78% |
UBS
Securities LLC |
|
0.00%3 |
0.00% |
TOTAL |
3.32% |
4.47% |
7.79% |
* Type of
financial instrument: 1'Right to
recall lent shares' and 2'Right to
substitute shares delivered as collateral' and 3'Depository
Receipt'
-
Chain of controlled
undertakings through which the holding is effectively being
held: Please see the full chain of control in the Transparency
Notification.
-
Additional information: The
disclosure obligation arose on 23 April 2018 due to the total
indirect holdings in voting rights of UBS Group AG, held directly
by controlled undertakings going above 3% and due the total
indirect holdings of UBS Group AG in equivalent financial
instruments, held directly by controlled undertakings going below
5%.
More information is available in
the transparency notification. A full version of the transparency
notifications is available on Ablynx website, under the section
Investors.
The articles of the association of
Ablynx NV provide for shareholders notification threshold of 3%, 5%
or a multiple of 5% of the total number of existing voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The
Company is headquartered in Ghent, Belgium. More information can be
found on www.ablynx.com.
On 29 January 2018, Sanofi made an
offer to acquire all of Ablynx's outstanding ordinary shares
(including shares represented by American Depository Shares (ADSs),
warrants and convertible bonds) at a price of €45 per share, which
represents an aggregate equity value of approximately €3.9 billion.
The proposed transaction was unanimously approved by both the
Sanofi and Ablynx Board of Directors. The offer is comprised of two
separate but concurrent tender offers: (i) a tender offer
under the laws of Belgium for all of the outstanding shares,
warrants and convertible bonds of Ablynx (the "Belgian Offer") and (ii) a tender offer under the
laws of the U.S. for all of the outstanding shares held by U.S.
holders and ADSs held by holders, wherever located (the "U.S. Offer"). The initial acceptance period of the
tender offers commenced on 4 April 2018 and will expire at 5:00
p.m. ET / 11:00 p.m. CET on 4 May 2018, subject to extension.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From May 2024 to Jun 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Jun 2023 to Jun 2024